Off-label use of medications is a widespread occurrence in the United States health care system. The practice stems in part from narrow approval indications, crafted to optimize the chance of success for the treatment, and also from enthusiastic clinicians and manufacturers and confirming data that are often suggestive if not definitive.
though again, substantial fractions of that use were concordant with compendium recommendations.
In dollar terms, annual sales of these 10 drugs totalled $11.9 billion. Based on the percentage of indicated uses, $2.4 billion, or 20% of sales, would be neither on-label nor NCCN Compendium concordant. That number, although not inconsequential, was driven principally by use of rituximab and bevacizumab. This $2.4 billion estimate also probably overstates the real price of off-label use. Because off-label use is likely to be less effective and thus of shorter duration than on-label use, the number of treatment starts for off-label uses is likely to exceed the dollar volume of sales for offlabel purposes.
What lessons can be drawn from this analysis of off-label oncology drug use and how are those lessons relevant to the national debate on improving cancer care and lowering the costs of treatment? First, it is encouraging that the vast majority of drug use is on-target, if not on-label. Most quality interventions aim for the Pareto principle 80/20 compliance rate, and in this study, 85% of drug use was either on-label or within accepted norms. The corollary is that over-worrying about off-label use of new oncology drugs would not bring much saving.
Many cancer centers have or are seeking pay-for-performance contracts designed to limit inappropriate use of expensive new drugs in cancer medicine. However, barriers to inappropriate use already exist, including the scientific literature, which guides clinicians and guidelines-makers toward recommendations, and the ability of third-party payers to deny claims for inappropriate use. That combination of "carrot and stick" seems to work quite effectively, and elaborate programs to further insist on compliance are not likely to bear major cost-saving fruit. Policymakers who seek to control the price of oncology drug services will need to look to other causes of expensive care, such as the actual price of the drugs, if they wish to curtail spending.
Not surprisingly, guideline-based care is at the center of this discussion. A potential criticism of high rates of compliance with the FDA indication or compendium-listed care is that compendia endorsements are too permissive. Nothing suggests that excessive permissiveness exists in the NCCN Guidelines, but the potential critique is a reminder that good guidelines make for good care. The evolving medical market is going to place increasing scrutiny on the quality and methodology of guidelines as it comes to increasingly demand adherence to those guideline standards.
